Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the safety and effect of interferon-alpha lozenges when used in combination with oseltamivir (Tamiflu) to treat influenza.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amarillo Biosciences, Inc.
• Collaborator: CytoPharm, Inc.
• Treatments: Interferon-alpha; Interferons; Oseltamivir

Criteria

Inclusion Criteria:

• fever >=38C

• one or more respiratory symptoms (e.g. cough, rhinorrhea or sore throat) plus one or more constitutional symptoms (e.g. chills, headache, malaise and myalgias)of < 48 hours' duration

• body weight > 40 kg

• positive for influenza A (nasal swab rapid test)

Exclusion Criteria:

• pregnancy/lactation

• history of depression or psychiatric disorders

• history of conditions that could complicate flu infection, such as chronic pulmonary, cardiac, renal, or metabolic disorders

• use of immunosuppressive therapy

• HIV infection